Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab, for the Greater China region, with an option for global rights. This comprehensive agreement, valued at up to $850 million, positions Biogen to potentially lead the charge in advancing the treatment of multiple myeloma (MM), a challenging hematological malignancy. The deal also grants Biogen control over the registrational biologics license application (BLA) already submitted to China’s National Medical Products Administration (NMPA) for patients with relapsed and refractory multiple myeloma (r/r MM). This move underscores Biogen’s commitment to expanding its oncology portfolio and addressing unmet needs in a critical therapeutic area.
A New Contender in the Anti-CD38 Immunotherapy Arena
Felzartamab represents a promising new entrant in the growing field of anti-CD38 immunotherapies, a class of drugs that has revolutionized the treatment paradigm for multiple myeloma. These therapies target the CD38 protein, which is highly expressed on myeloma cells, leading to their destruction. The acquisition by Biogen signals a strong belief in felzartamab’s potential to compete with and potentially offer distinct advantages over existing treatments.
A key differentiator for felzartamab, as highlighted by TJ Biopharma’s BLA submission, is its promising clinical trial data. These studies reportedly demonstrate comparable efficacy and safety profiles to the current market leader, daratumumab, when administered in combination with established oral therapies such as dexamethasone and lenalidomide. This comparison is particularly significant, as daratumumab, marketed as Darzalex by Janssen Biotech, has become the de facto standard of care in many treatment regimens for MM.
The Competitive Landscape: Darzalex and the Quest for Convenience
The multiple myeloma market is substantial and growing. In 2025, anti-CD38 antibodies were utilized in 35.8% of all r/r MM patients across eight major global markets (the US, France, Germany, Italy, Spain, the UK, Japan, and China), representing a significant market size of $7.6 billion, according to data from GlobalData’s patient-based forecast. Darzalex has historically dominated this segment, accounting for an impressive 87.5% of global anti-CD38 utilization and generating $7.1 billion in sales in 2025.
Despite its efficacy and favorable safety profile, Darzalex presents a notable challenge for both patients and healthcare providers due to its administration method. The intravenous infusion of Darzalex can last up to seven hours, requiring lengthy clinical visits and representing a considerable burden. This protracted treatment duration has fueled a demand for more convenient administration options.
Felzartamab appears to directly address this unmet need. TJ Biopharma has reported that its immunotherapy boasts a significantly shorter administration time of just 1.5 hours. This reduction in infusion time could translate into improved patient experience, reduced strain on healthcare resources, and potentially allow for more flexible treatment scheduling.
However, the competitive landscape is not static. Janssen Biotech is actively developing and trialing subcutaneous formulations of its anti-CD38 therapy. Darzalex Faspro, the subcutaneous version of Darzalex, is currently undergoing trials in China for MM. This less invasive formulation offers a dramatically reduced administration time of merely 3-5 minutes and, importantly, opens the gateway to home administration, a paradigm already established in the US. Should Darzalex Faspro gain approval in China, it would undoubtedly raise the competitive bar considerably for felzartamab, primarily based on its unparalleled convenience.
Strategic Implications for Biogen and the Chinese Market
The acquisition of felzartamab by Biogen is particularly strategic for its presence in the Greater China region. The manufacturing of felzartamab will be retained by TJ Biopharma at its state-of-the-art Good Manufacturing Practice (GMP) facility in Hangzhou, China. This domestic production capability is poised to make felzartamab China’s first domestically manufactured anti-CD38 immunotherapy for multiple myeloma.
This aligns perfectly with China’s national strategy to bolster its domestic pharmaceutical manufacturing sector. The Chinese government actively supports local manufacturers through a suite of policy incentives, including volume-based procurement agreements, fiscal subsidies, tax relief, and expedited regulatory pathways. By establishing domestic manufacturing for felzartamab, Biogen can potentially leverage these government initiatives, potentially leading to cost efficiencies and greater market access within China.
However, the success of felzartamab in China hinges not only on its therapeutic profile and manufacturing advantages but also on building trust among Chinese prescribers. Clinicians are keenly awaiting the publication of Phase III clinical trial data for felzartamab. Robust and compelling data from these pivotal trials will be crucial in swaying physician confidence and encouraging widespread adoption.
GlobalData’s projections offer an optimistic outlook for felzartamab’s performance in China. The patient-based forecast anticipates that felzartamab could capture 14.6% of the Chinese MM market by 2029, a market estimated to be worth $458 million. This projection suggests that, if successful, felzartamab could carve out a significant niche even with the presence of established global players.
The ultimate question remains whether Biogen will deem the advantages of domestic capacity and TJ Biopharma’s innovative approach sufficient to mount a serious and sustained challenge to incumbent therapies like Darzalex and its evolving subcutaneous formulation. The company’s intention to lead the commercial efforts post-approval signifies a strong commitment to maximizing felzartamab’s potential.
Background and Chronology of the Deal
The announcement on April 20, 2026, marks the culmination of negotiations and due diligence between Biogen and TJ Biopharma. While specific details regarding the initial discovery and preclinical development of felzartamab by TJ Biopharma are not extensively detailed in the announcement, it is understood that TJ Biopharma has been actively developing this candidate for several years, aiming to bring a differentiated immunotherapy to market.
The submission of the BLA to the NMPA represents a critical milestone, indicating that TJ Biopharma has amassed sufficient data to support the drug’s safety and efficacy for regulatory review. Biogen’s decision to acquire rights at this stage suggests confidence in the strength of TJ Biopharma’s clinical evidence and the regulatory pathway.
The timeline leading up to this announcement likely involved:
- Early Development and Preclinical Research: TJ Biopharma identifying CD38 as a target and developing felzartamab.
- Clinical Trial Initiation and Execution: TJ Biopharma conducting Phase I, II, and potentially early Phase III trials for felzartamab in r/r MM.
- BLA Submission: TJ Biopharma submitting its application to the NMPA, signaling readiness for potential market approval.
- Biogen’s Due Diligence and Negotiation: Biogen evaluating felzartamab’s scientific merit, market potential, and TJ Biopharma’s manufacturing capabilities, leading to the acquisition agreement.
- Announcement of the Deal: The formal public announcement of Biogen’s acquisition of rights and the financial terms of the agreement.
The $850 million valuation, payable in milestones, reflects the significant potential Biogen sees in felzartamab, particularly within the burgeoning Chinese pharmaceutical market. This investment underscores Biogen’s long-term strategy to strengthen its oncology pipeline and capitalize on innovative therapies that offer clear clinical advantages.
Broader Impact and Future Outlook
The acquisition of felzartamab by Biogen has several broader implications for the pharmaceutical industry and patient care:
- Increased Competition in MM Treatment: The entry of a potentially superior infusion-time therapy, manufactured domestically, could drive down prices and improve access for Chinese patients.
- Validation of Chinese Biopharmaceutical Innovation: The deal highlights the growing capabilities of Chinese biopharmaceutical companies like TJ Biopharma in developing innovative therapies that attract interest from global pharmaceutical giants.
- Shifting Treatment Paradigms: If felzartamab proves successful and gains widespread adoption, it could accelerate the trend towards shorter infusion times and more patient-centric treatment models in oncology.
- Biogen’s Strategic Positioning: This acquisition bolsters Biogen’s presence in oncology, a key growth area, and provides a strong foothold in the critical Greater China market. It also diversifies its portfolio beyond its established neuroscience franchises.
The coming months and years will be critical as felzartamab navigates the regulatory approval process with the NMPA and faces the competitive pressures of the evolving multiple myeloma treatment landscape. The success of this venture will depend on a combination of robust clinical data, effective commercial strategies, and the ability to foster strong relationships with healthcare providers and patients in China and potentially beyond. Biogen’s substantial investment signals a clear intent to make felzartamab a significant player in the fight against multiple myeloma.
Leave a Reply